Specifically for patients with PCNS‐ALCL, a systematic review of reported cases found that ALK‐positive tumours were associated with superior 2‐year OS rates compared to ALK‐negative neoplasms (71% vs. 22%).151. This evidence concerns the gene ALK and neoplasm.